Premium
Intravenous cisplatin for superficial bladder tumors
Author(s) -
Needles Burton,
Yagoda Alan,
Sogani Pramod,
Grabstald Harry,
Whitmore Willet F.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19821101)50:9<1722::aid-cncr2820500911>3.0.co;2-a
Subject(s) - medicine , cystoscopy , lamina propria , nausea , vomiting , urinary bladder , carcinoma in situ , urology , biopsy , cisplatin , urinary system , cytology , carcinoma , surgery , chemotherapy , radiology , pathology , epithelium
Cisplatin, 1.25 mg/kg IV QM, was administered to 15 patients with recurrent flat carcinoma in situ and/or bladder tumors confined to the mucosa and lamina propria. All patients had a history of multiple transurethral resection and 4 had received prior irradiation and two prior intravesical thiophosphoramide. Response was evaluated by urinary cytologic findings, cystoscopy and biopsy. Of 14 adequately treated cases, four (28%) had disappearence of all visible lesions, cystoscopically, for a median of eight months (range, 8–18), and six exhibited transiently a >50% decrease in the number of tumors. However, no patient demonstrated a complete remission—all had persistently positive urinary cytologies. Nausea and vomiting, even at this dose level, was significant and at times, severe. Cisplatin, in the dose and schedule used, was found to be ineffective in controlling low‐stage bladder tumors. Cancer 50:1722‐1723, 1982.